Description

According to StrategyHelix, the global stress management market is expected to increase by US$ 4.8 billion during 2022-2028, expanding at a CAGR of 3.8% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for stress management. The global stress management market is segmented on the basis of product, age group, end user, and region. Based on product, the global stress management market is categorized into medications, devices. The medications segment held the largest share of the global stress management market in 2021 and is anticipated to hold its share during the forecast period. On the basis of age group, the global stress management market has been segmented into adults, children, elderly. Globally, the adults segment made up the largest share of the stress management market. By end user, the global stress management market has been segmented into ambulatory surgical centers, hospitals and clinics, others. The hospitals and clinics segment was the largest contributor to the global stress management market in 2021. Geographically, the global stress management market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). Europe is estimated to account for the largest share of the global stress management market.

The global stress management market is highly competitive. The leading players in the stress management market include Abbott Laboratories, Allergan plc, Apple Inc., AstraZeneca plc, Bausch Health Companies Inc., Bristol Myers Squibb (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Lupin Limited, Merck & Co., Mylan N.V., Pfizer Inc., Samsung Electronics Co. Ltd., Takeda Pharmaceutical Co. Ltd. Competitive landscape gives a description of the competitive nature of the global stress management market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the stress management market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: medications, devices
Age group: adults, children, elderly
End user: ambulatory surgical centers, hospitals and clinics, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Abbott Laboratories, Allergan plc, Apple Inc., AstraZeneca plc, Bausch Health Companies Inc., Bristol Myers Squibb (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Lupin Limited, Merck & Co., Mylan N.V., Pfizer Inc., Samsung Electronics Co. Ltd., Takeda Pharmaceutical Co. Ltd.

Key Benefits for Stakeholders

– Get a comprehensive picture of the global stress management market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Stress management market overview
Part 3. Market breakdown by product
– Medications
– Devices
Part 4. Market breakdown by age group
– Adults
– Children
– Elderly
Part 5. Market breakdown by end user
– Ambulatory surgical centers
– Hospitals and clinics
– Others
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– Abbott Laboratories
– Allergan plc
– Apple Inc.
– AstraZeneca plc
– Bausch Health Companies Inc.
– Bristol Myers Squibb (BMS)
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– GSK plc
– Johnson & Johnson
– Lupin Limited
– Merck & Co.
– Mylan N.V.
– Pfizer Inc.
– Samsung Electronics Co., Ltd.
– Takeda Pharmaceutical Co., Ltd.
About StrategyHelix
Disclaimer